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The term autoimmune rheumatic diseases (ARDs) encom-
passes a heterogeneous group of conditions characterized by
joint involvement along with a wide spectrum of systemic
manifestations. The most common ARDs are rheumatoid
arthritis (RA) and systemic lupus erythematosus (SLE).
Nevertheless, all these conditions share similar pathophysio-
logical mechanisms [1, 2] and a common risk of developing
a process of accelerated atherosclerosis [3]. In this regard,
in this special issue J. Amaya-Amaya and colleagues dis-
cussed the mechanisms associated with the increased risk of
cardiovascular disease (CVD) in patients with autoimmune
diseases. These authors emphasize the relevance of the CVD
in rheumatic conditions and its connection with inflamma-
tion and autoimmunity. They also highlight the need of a
more aggressive management of these conditions, both of
disease activity and classic cardiovascular risk factors. A good
example of accelerated atherosclerosis in the setting of an
ARD is SLE, inwhich endothelial dysfunction, an early step in
the atherogenesis process, is observed before cardiovascular
events can occur. With respect to this, A. Mak and N. Y. Kow
performed a comprehensive review of the mechanisms that
are involved in endothelial damage.These authors focused on
the factors involved in endothelial damage and repair and,
therefore, in the development of CVD in patients with SLE.
They discussed the relevant role of factors such as type 1
interferon, proinflammatory cytokines, inflammatory cells,
immune complexes, costimulatory molecules, neutrophils
extracellular traps, lupus-related autoantibodies, oxidative
stress, and dyslipidemia that along with the aberrant func-
tion of the endothelial progenitor cells lead to endothelial
dysfunction and increased susceptibility to develop CVD
in patients with SLE. Based on these lines of evidence,
the authors’ claim is in favor of early intervention at the
preclinical stage of atherogenesis in these patients.
Interestingly, damage and activation of vascular endothe-
lial cells are implicated in the pathogenesis of SLE [4]. Angio-
genic factors play a significant role in vascular permeability,
vascular growth, and inflammatory response observed in
SLE. L. Zou and colleagues assessed the serum levels of
3 angiogenic factors in SLE and their clinical significance.
These authors disclosed that the levels of PlGF, bFGF, and
VEGF are higher in SLE patients with active disease than
in those with inactive SLE. Their findings may have a
potential interest in the management and development of
future therapies for autoimmune diseases.
Besides cardiovascular complications, renal disease and
the risk of infection overshadow the outcome of patients
with SLE [5, 6]. In this regard, as reported in this special
issue by E. Cairoli and colleagues, end-stage renal disease
(ESRD) is an important cause of morbidity and mortality in
patients with SLE. These authors analyzed the outcome and
prognostic factors of renal transplantation in patients with
ESRD due to SLE. They assessed 50 renal transplantations
that were performed in 40 SLE patients. The most frequent
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underlying lupus nephropathy that led to ESRD was type
IV (72.2%). Graft failure occurred in 30% transplantations
and the most common cause of graft failure was chronic
allograft nephropathy. The patient survival rate was high.
Recurrence of lupus nephritis in renal allograft was only
observed in 1 patient. In this study the presence of anti-HCV
antibodies and the type of donor source were related to the
development of graft failure. According to these results, renal
transplantation appears to be a good alternative for renal
replacement therapy in patients with SLE.
Since some studies indicate an increased incidence of
tuberculosis in patients with SLE [7], a diagnosis of latent
tuberculosis infection is of major importance in these
patients. M. D. M. Arenas Miras and colleagues report in
this special issue a study to compare the tuberculin skin test
and the newer T.SPOT.TB test to diagnose latent tuberculosis
infection in SLE. Unlike T.SPOT.TB results, the tuberculin
skin test results were negatively affected by corticosteroid
and immunosuppressive therapy. Because of that, the authors
support the use of the T.SPOT.TB test in SLE patients
receiving corticosteroids or immunosuppressive drugs.
Patients with RA also have a higher risk for atheroscle-
rosis [8, 9]. E. Gómez-Bañuelos and colleagues from Mexico
evaluated the association between membrane expression of
CD36 in peripheral blood mononuclear cells (PBMC) and
carotid intima-media thickness (cIMT) in patients with RA
in order to evaluate the association of membrane expression
of CD36 with subclinical atherosclerosis. Other molecules
related to cardiovascular risk such as ox-LDL, IL-6, and
TNF𝛼were also tested. A lowmembrane expression of CD36
in PBMC from patients with RA presenting with subclin-
ical atherosclerosis and increased serum proinflammatory
cytokines was observed.
Proteoglycan-induced arthritis (PGIA) is a widely used
model based on the cross-reactivity of injected foreign (usu-
ally human) PG and mice self-PG. L. L. W. Ishikawa and col-
leagues evaluated the arthritogenicity of bovine proteoglycan
(PG) and found that it can be used as an alternative antigenic
source to PG-induced arthritis for the study of many RA
aspects, including the immunopathogenesis of the disease
and also the development of new therapies.
Anticitrullinated peptide antibodies (ACPA) are detected
in the sera of patients with RA and have a profound role in
the diagnosis of the disease [10]. M. L. Dı́az-Toscano and
colleagues evaluated the performance of using two assays
for ACPA: second-generation anticitrullinated cyclic pep-
tides antibodies (anti-CCP2) and antimutated citrullinated
vimentin (anti-MCV) antibodies for the diagnosis of RA.
Their study suggest that adding the assay of anti-MCV
antibodies to the determination of anti-CCP2 increases the
sensitivity for detecting seropositive RA, and authors propose
the use of both assays in the initial screening of RA in
longitudinal studies, including early onset of undifferentiated
arthritis.
Since clinical response of biologic agents in RA can be
influenced by their pharmacokinetics and immunogenicity,
D.Mazilu and colleagues evaluated the concordance between
serumdrug and antidrug levels as well as the clinical response
in RA patients treated with biological agents who experience
their first disease exacerbation while being on a stable
biologic treatment. Detectable biologic drug levels correlated
with a better clinical response in patients experiencing their
first RA inadequate response while being on a stable biologic
treatment with rituximab, infliximab, and etanercept (ETN).
Interleukin-6 (IL-6), a cytokine that can facilitate autoim-
mune phenomena, amplify acute inflammation, and promote
the evolution into a chronic inflammatory state, has a pivotal
role in synovitis, bone erosions, and the systemic features of
RA [11]. A comprehensive review on IL-6 and the rationale for
blocking this cytokine in RA are also presented in this special
issue.
Pharmacogenomics, the study of how genes affect a
person’s response to drugs, will allow the development of
tailored drugs to treat a wide range of health problems,
including RA and many others. A. Lima and colleagues
report in this special issue the role of methylenetetrahydrofo-
late reductase (MTHFR) C677T, aminoimidazole carboxam-
ide adenosine ribonucleotide transformylase (ATIC) T675C
polymorphisms, and clinicopathological variables in clinical
response to methotrexate (MTX) in Portuguese patients with
RA. MTHFR 677TT and ATIC 675T carriers were associated
with over 4-fold increased risk for nonresponse to MTX.
Authors suggest the use of these genotypes combined with
clinicopathological data to assist clinicians in personalizing
RA treatment.
We hope that readers will enjoy this issue and find
accurate data and updated reviews on the most common
ARDs.
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Cervera, “Epidemiology and management of refractory lupus
nephritis,” Autoimmunity Reviews, vol. 10, no. 11, pp. 655–663,
2011.
[6] M. T. Arango, Y. Shoenfeld, R. Cervera, and J. M. Anaya,
“Infection and autoimmune diseases,” in Autoimmunity. From
Bench to Bedside, J. M. Anaya, Y. Shoenfeld, A. Rojas-Villarraga,
R. A. Levy, and R. Cervera, Eds., pp. 303–320, Universidad del
Rosario, Bogota, Colombia, 2013.
BioMed Research International 3
[7] J.-G. Erdozain, G. Ruiz-Irastorza, M.-V. Egurbide, A. Martinez-
Berriotxoa, and C. Aguirre, “High risk of tuberculosis in
systemic lupus erythematosus?” Lupus, vol. 15, no. 4, pp. 232–
235, 2006.
[8] M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, and J. Martin,
“Rheumatoid arthritis: a disease associated with accelerated
atherogenesis,” Seminars in Arthritis and Rheumatism, vol. 35,
no. 1, pp. 8–17, 2005.
[9] F. Buttgereit, G. Burmester, and B. J. Lipworth, “Inflammation,
glucocorticoids and risk of cardiovascular disease,” Nature
Clinical Practice Rheumatology, vol. 5, no. 1, pp. 18–19, 2009.
[10] K. Goldman, S. Gertel, and H. Amital, “Anti-citrullinated
peptide antibodies is more than an accurate tool for diagnosis
of rheumatoid arthritis,” Israel Medical Association Journal, vol.
15, no. 9, pp. 516–519, 2013.
[11] J. E. Fonseca, M. J. Santos, H. Canhão, and E. Choy,
“Interleukin-6 as a key player in systemic inflammation and
joint destruction,” Autoimmunity Reviews, vol. 8, no. 7, pp. 538–
542, 2009.
